Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies

NCT06948097 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

NIH

Sponsor class

Conditions

Lung Transplantation

Interventions

DRUG: fostamatinib
DRUG: Placebo

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)